Share
![cover art for How might the MORPHO trial of gilteritinib impact clinical practice?](https://res.cloudinary.com/pippa/image/fetch/h_750,w_750,f_auto/https://assets.pippa.io/shows/undefined/1585645708468-f1820b05797bc1563ae18cf50ab2ecce.jpeg)
AML Hub
How might the MORPHO trial of gilteritinib impact clinical practice?
•
The AML Hub spoke to Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK at ASH 2023. We asked, How might the MORPHO trial of gilteritinib impact clinical practice?
More episodes
View all episodes
What were your highlights from ASH 2023?
03:36|During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub.What are the challenges associated with CAR T-cell therapy in patients with AML?
09:19|During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therapy in patients with AML?Risk stratification and guidelines in AML management
11:49|The AML Hub was pleased to speak to Gail Roboz, Weill Cornell Medicine, New York, US, and Naval Daver, MD Anderson Cancer Center, Houston, US. We asked about risk stratification and guidelines in acute myeloid leukemia (AML) management. Firstly, Roboz and Daver discuss the impact of blast count on the diagnosis of AML and how a patient's mutational profile can affect treatment decisions. They highlight available, effective lower-intensity and targeted therapies and a potential transition to a fully genomic- and cytogenetic-based classification of AML. Finally, they discuss current patient selection strategies for intensive induction chemotherapy and future directions in AML treatment.1. How are new fludarabine conditioning combinations impacting transplant outcomes?
06:04||Season 1, Ep. 1During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessaloniki, Thessaloniki, GR. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes?Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of fludarabine + treosulfan, which followed on from previous studies exploring treosulfan. Gavriilaki details the study design and patient population, explaining which comparative therapies were used and why. Finally, Gavriilaki outlines different studies presented at EBMT covering fludarabine combinations for patients with AML and MDS.13. Should pre-transplant MRD be used to guide treatment in AML?
06:08||Ep. 13During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatment in AML?Nagler begins by discussing the importance of MRD in AML treatment and transplantation. He highlights the significance of MRD in different settings as a prognosis factor and describes the result of his study presented at EHA2021. Finally, he outlines the current treatment landscape for transplants in relation to MRD status and makes recommendations for MRD-positive patients.12. Should pre-transplant MRD be used to guide treatment in AML?
13:54||Ep. 12During the EHA2021 Virtual Congress, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)?Craddock begins by outlining the reasons for the increased use of allogeneic transplant and reviews data that discuss the exclusion criteria and benefits of transplant. He goes on to discuss how patient outcomes could be improved and the importance of post-transplant maintenance. Finally, he highlights the need to generate prospective data, referring to the ongoing studies COSI and AMADEUS.11. Should pre-transplant MRD be used to guide treatment in AML?
05:03||Ep. 11During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)? Ossenkoppele begins by outlining emerging techniques in MRD, such as next-generation sequencing. He goes on to describe how risk category and MRD status can inform treatment decisions, such as for allogeneic stem cell transplant.1. Can HMA maintenance therapy improve eligibility for HSCT?
05:22||Ep. 1During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT? Ravandi begins by highlighting the limited maintenance approaches for patients with AML. He continues with the promising results from the QUAZAR AML-001 study evaluating oral azacitidine (CC-486), an oral hypomethylating agent, which can be used for maintenance and to improve eligibility for hematopoietic stem cell transplantation.